Adds details on unit performance in bullet 3, CEO comment in bullet 4

Feb 25 (Reuters) - Danish biosolutions company Novonesis NSISb.CO reported weaker-than-expected organic sales growth for the fourth quarter on Wednesday, held back by flat revenue in the Agriculture, Energy & Tech business.

While the unit's euro sales were positively impacted by the 2025 acquisition of the remaining stake in Feed Enzyme Alliance, this boost was offset by currency headwinds elsewhere, Novonesis said in a statement, another European chemicals group grappling with strong home currencies eroding reported numbers.

KEY DETAILS

• Novonesis delivered quarterly organic growth of 4%, against 5.2% seen in a company-provided consensus.

• The biggest miss to analysts' expectations came within the Planetary Health segment, where Agriculture, Energy & Tech saw no growth in euros versus 7% expected by analysts.

• Negative timing in the agriculture segment and a tough comparison period in tech hindered growth, despite positive development in the energy business area, the company said in a presentation.

• "We delivered double digit growth in bioenergy in Q4, and we're already seeing a strong start to 2026," CEO Ester Baiget told Reuters.

• Quarterly adjusted earnings before interest, taxes, depreciation and amortization (EBITDA) were 364.6 million euros ($429.9 million), 10 million euros below consensus.

• For 2026, Novonesis guides for organic sales growth between 5-7% and a higher adjusted EBITDA margin of 37-38%, including currency headwinds of about 50 bps year-on-year.

• Jyske Bank analysts said that late‑year signs of consumer softness were hardly encouraging after a strong year.

• Novonesis' shares have lost around 20% of their value since peaking in June 2025. They were down less than 2% at 1135 GMT.

($1 = 0.8480 euros)